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ABSTRACT  
Background: Previous reports identifying discordance between multi-parameter tests at the 
individual patient level have been largely attributed to methodological shortcomings of multiple 
in silico studies. Comparisons between tests, when performed using actual diagnostic assays, have 
been predicted to demonstrate high degrees of concordance. OPTIMA prelim compared predicted 
risk stratification and subtype classification of different multi-parameter tests performed directly 
on the same population.  
Methods: 313 women with early breast cancer were randomised to standard (chemotherapy and 
endocrine therapy) or test-directed (chemotherapy if Oncotype DX™ recurrence score >25) 
treatment. Risk stratification was also determined with, Prosigna™(PAM50), MammaPrint™, 
MammaTyper™, NexCourse Breast™ (IHC4-AQUA™) and conventional IHC4 (IHC4). Subtype 
classification was provided by Blueprint™, MammaTyper™ and Prosigna™.  
Results: Oncotype DX™ predicted a higher proportion of tumours as low risk (82.1%; 95%CI 77.8-
86.4%) than were predicted low/intermediate risk using Prosigna™ (65.5%; 95%CI 60.1-70.9%), 
IHC4 (72.0% 95%CI 66.5-77.5), MammaPrint™ (61.4%; 95%CI 55.9-66.9%) or NexCourse Breast™ 
(61.6%; 95%CI 55.8-67.4%). Strikingly, the five tests showed only modest agreement when 
dichotomising results between high versus low/intermediate risk. Only 119 (39.4%) tumours were 
classified uniformly as either low/intermediate risk or high risk, 183 (60.6%) were assigned to different 
risk categories by different tests, although 31.1% (94) showed agreement between four/five tests. All 
three subtype tests assigned 59.5-62.4% of tumours to luminal A subtype, but only 121 (40.1%) were 
classified as luminal A by all three tests and only 58 (19.2%) were uniformly assigned as non-luminal 
A. Discordant subtyping was observed in 123 (40.7%) cases. 
Conclusions: Existing evidence on the comparative prognostic information provided by different tests 
suggests current multi-parameter tests provide broadly equivalent risk information for the population 
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of women with ER-positive breast cancers. However, for the individual patient, tests may provide 
differing risk categorisation and subtype information. 
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INTRODUCTION 
For over 40 years (1-3) the impact of tumour molecular markers on patient outcome and 
treatment response has been central to breast cancer management. Gene-expression profiling (4;5) 
to describe the intrinsic subtypes of breast cancer was followed by the independent development, 
in 2004, of the first multi-parameter molecular diagnostic assay stratifying breast cancer patients 
with estrogen receptor (ER) positive disease based on risk of relapse following treatment (6). The 
past decade saw a rapid expansion in the number of such multi-parameter molecular residual risk 
tests for breast cancer patients (see (7)). These herald an era of more personalised medicine due to 
their potential to inform rational treatment decisions on a patient-by-patient basis. The initial goal was 
to identify patients who, despite “favourable” clinico-pathological characteristics, have a poor 
outcome following conventional endocrine treatment and to advise aggressive therapy, which may 
reduce relapse risk.  
Over time, interest has also grown in the potential for multi-parameter assays to predict 
chemo-sensitivity (8;9). These tests may also allow an estimate of the intrinsic chemotherapy 
sensitivity of tumours, reducing the importance of stage information. There are women who gain 
little from chemotherapy and women who have clinically significant gains. There is therefore a 
rationale for using stratified medicine to identify patients who may safely avoid toxicities associated 
with chemotherapy.  
The OPTIMA trial (7) is designed as a prospective test of the effectiveness of multi-parameter 
testing in identifying the subgroup of women with breast cancer (amongst those who would be 
routinely offered adjuvant chemotherapy, based on conventional criteria), whose tumours are 
intrinsically insensitive to chemotherapy and for whom such treatment offers only toxicity and delay 
in starting more effective adjuvant endocrine therapy, and radiotherapy, without any clinically 
meaningful additional benefit. A key objective of “OPTIMA prelim”, the in-built feasibility phase 
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of OPTIMA, was to evaluate the performance of alternative multi-parameter tests, to aid selection 
of a test for the main study that would ensure the results of such a trial be robust and broadly 
applicable to the patient population, both now and in the future. Critical to this decision was the 
ability to compare test performance at both the population and individual patient level. Existing 
data directly comparing individual test performance is limited. A series of studies performing 
statistical comparisons between tests suggest that, at a population level, four tests (IHC4, PAM50, 
BCI and Oncotype DX) ™ provided broadly equivalent prognostic information on the risk of 
relapse up to five years post treatment (10-12). Further studies, based largely on in silico 
reconstruction of existing tests from publically available gene expression data sets suggest a 
statistically significant degree of discordance between signatures at the individual patient level 
(13-17). These observations are predominantly attributed to methodological differences due the in 
silico reconstruction of signatures (15;17). This thesis has not, to date, been robustly tested using 
actual test methodologies. Limited data shows that concordance between different tests in 
assigning patients to similar risk groups is low (10). This is consistent with the marked differences 
in genes measured by different tests (See Supplementary Table 1) and with the relatively modest 
predictive value, in terms of recurrence, offered by these tests at the individual patient level. Here 
we report the direct patient level comparison of multiple commercial residual risk profiles in the 
OPTIMA prelim study, performed to gather information on their performance.  
 
MATERIALS AND METHODS 
Recruitment and patient samples 
OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-
parameter Analysis preliminary study, ISRCTN42400492) (18) is a multi-centre study that randomised 
women aged ≥40 with ER-positive HER2-negative early breast cancer and either 1-9 involved axillary 
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nodes or tumour size ≥30mm (if node-negative) between standard treatment (chemotherapy followed 
by endocrine therapy) and test-directed therapy (7). In the test-directed arm an Oncotype DX™ test 
was performed; patients with Recurrence Score (RS) >25 (“high” risk) were assigned chemotherapy 
followed by endocrine therapy, those with RS ≤25 (“intermediate/low” risk) received endocrine 
therapy alone. Chemotherapy, selected from regimens commonly used in the UK NHS, was specified 
at patient registration. The study was partially blinded so that neither patients nor referring centres 
were aware of whether chemotherapy was assigned on the basis of Oncotype DX™ RS or by 
randomisation to the standard treatment arm. Central re-testing of ER and HER2 status was performed 
on all patients. Following confirmation of eligibility, samples were sent to Genomic Health for 
Oncotype DX™ assays to be performed with funding from the OPTIMA prelim study.  No patient 
outcome data is available for this analysis. All patients gave written informed consent to participate 
in the study. The study was approved by the South East Coast - Surrey Research Ethics Committee. 
To facilitate the comparison of alternative tests a number of test vendors were approached for 
support (Supplementary Table 2). Ultimately five tests in addition to Oncotype DX™ were included 
in the OPTIMA prelim study: MammaPrint/BluePrint™, Prosigna™ (PAM50), MammaTyper™, 
NexCourse Breast by Aqua™ (IHC4-AQUA) and IHC4 by conventional immunohistochemistry. 
Multi-parameter assays were performed irrespective of patient randomisation. Vendors that did not 
participate expressed concerns about transposing specific tests into novel applications. 
 
Residual tumour samples from patients were collected at a central good clinical laboratory 
practice pathology repository (Edinburgh UK). Tissue MicroArrays (TMAs) were constructed as 
previously described (19) using triplicate 0.6mm cores. TMA sections, tissue sections or extracted 
mRNA were provided either to the Ontario Institute for Cancer Research (Prosigna™; IHC4: ER, 
PgR and Ki67 by quantitative image analysis (Ariol) using standard IHC with HER2 testing by ISH at 
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UCL Advanced Diagnostics) or to Genoptix (IHC4-AQUA), Agendia 
(MammaPrint™/Blueprint™) and Stratifyer (MammaTyper™). Results from individual tests were 
collated at the Warwick Clinical Trials Unit (CTU) for analysis. 
 
Statistical Analysis 
OPTIMA prelim was designed to recruit 300 patients to enable the kappa value for 
agreement between tests to be estimated with good accuracy. Assuming 70% of patients would be 
assigned to no chemotherapy by the test and the true kappa value was 0·8 (14), this would provide 
a lower 95% confidence limit of 0·73. These numbers were also sufficient to allow for the assumed 
proportion of patients assigned to no chemotherapy to vary from 55% to 80% (lower confidence 
limit for kappa varied from 0·74 to 0·72 respectively). 
The proportion of tumours assigned to risk groups and/or subtypes was determined. The 
kappa coefficient and associated 95% confidence interval (95%CI) was used to assess agreement 
between tests. The predicted benefits of endocrine therapy with or without chemotherapy 
individualised to patients were estimated using two nomograms, Adjuvant! (20) (version 8, 
without correction for HER2 status) and PREDICT (21-23). A multivariable logistic regression 
model using stepwise elimination was performed to determine factors predicting discordant cases. 
To explore the post hoc hypothesis that individual tests were more likely to agree at the extremes 
of their ranges, two-by-two scatterplots for the tests that provide risks scores and agreement charts 
for the categorisation of tumours were constructed (24). Statistical analyses were performed using 
the SAS statistical package (version 9.3; SAS Institute Inc., Cary, NC, USA) and R version 3·0·3 
(25). All statistical tests were two-sided and a p-value of less than 0.05 was considered statistical 
significant.  
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RESULTS 
Patients 
Between October 2012 and June 2014, 313 patients were randomised from 35 UK hospitals 
(see the Notes), of whom 302 had samples available for multi-parameter testing (Table 1).  Eleven 
patients were excluded from multi-parameter testing; four withdrew consent, one was ineligible 
and samples for six patients were insufficient for testing (Supplementary Figure 1).  
 
Results from predictive nomograms 
The majority of patients recruited were either at intermediate (74.8%) or high (21.2%) risk 
using the Nottingham Prognostic Index (NPI) (26). All 12 patients with lower risk NPI scores 
(<3·4) had tumours >3·0 cm. The median 10 year overall survival estimated by PREDICT (21-23) 
or Adjuvant! (20) differed by 6·2-8·4% reflecting expected differences between the risk estimate 
provided by these tools (Table 2). 
 
Multi-parameter tests 
Results from all tests were available for 236 (78.1%) patients.  One patient on the standard 
arm had insufficient invasive tumour for Oncotype DX™ testing, but sufficient for alternative 
testing. Test results were unobtainable from Prosigna™ for three patients; from MammaTyper™ 
for four patients; from MammaPrint™ for four patients and BluePrint™ for seven patients. IHC4 
and IHC4-AQUA™ could not be determined for 45 (14.9%) and 31 (10.3%) patients respectively, 
reflecting use of TMAs for this assessment.  
Risk Scores 
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Five tests provided quantitative or semi-quantitative risk scores and a pre-defined 
categorised risk assessment (low, intermediate, high). For OPTIMA prelim, Oncotype DX™ RS 
was dichotomised around 25 separating “low/intermediate” from “high” risk cases as only patients 
with a high risk of recurrence were allocated chemotherapy (Table 3). Using this approach for all 
tests (Supplementary Methods), the proportion of cases classified as low/intermediate risk for 
Oncotype DX™ was 82.1% (95%CI 77.8-86.4%), 72.0% (95%CI 66.5-77.5%) for IHC4, 65.6% 
(95%CI 60.1-70.9%) using Prosigna™ risk of recurrence score including proliferation and tumour 
size, 61.6% (95%CI 55.8-67.4%) for IHC4-AQUA, and 61.4% (95%CI 55.9-66.9%) for 
MammaPrint™ (Table 3).  
Agreement between tests when patients were subdivided into combined low/intermediate 
versus high-risk groups using predefined cut-points was modest; Kappas ranged from 0·33 (95%CI 
0·21-0·44) between MammaPrint™ and IHC4 to 0·60 (95%CI 0·50-0·70) between IHC4 and 
IHC4-AQUA (Table 4, Supplementary Table 3). Only 119 (39.4%) tumours were uniformly 
classified as either low/intermediate or high by all five test; 30.8% (n=93) tumours were classified 
as low/intermediate risk by all tests, a further 8.6% (n=26) classified as high risk by all tests. The 
majority (60.6%; n=183) of cases gave no consensus result across all five tests. However for 31.1% 
of cases (n=94) agreement was observed in four of the five tests. There were also no clear 
differences between tests in terms of the agreement with other tests (Table 5). No statistically 
significant differences in clinico-pathological features between tumours that were concordant or 
discordant were observed (Supplementary Table 4). There is no evidence from the scatterplots 
of risk scores that individual tests were more likely to agree at the extremes of their ranges 
(Supplementary Figure 2). Disagreement spanning one of three risk categories was common, e.g. 
low risk to intermediate risk, and disagreement spanning two categories was not infrequent, i.e. 
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low risk to high risk (Figure 1; Supplementary Table 5). An exploratory analysis using a 
categorisation of low versus intermediate/high risk to more closely reflect current test usage was 
performed (Supplementary Tables 6-7) again modest agreement between tests was observed. 
 
Intrinsic Subtypes  
The three tests that provide subtype information categorised similar proportions of patients 
as having “luminal A” tumours (BluePrint™: 60.7%; 95%CI 55.2%-66.3%, Prosigna™: 59.5%; 
95%CI 53.9-65.1% and MammaTyper™ (combined luminal A and low-risk luminal B): 62.4%; 
95%CI 56.9-67.9%). Thirteen (4.3%) patients were classified as having HER2 enriched/positive 
tumours by at least one test. Two (0.7%) patients had basal like tumours using Prosigna™ 
subtyping; one of whom also had a basal like tumour using BluePrint™ but triple negative breast 
cancer using MammaTyper™. All these patients were classified as ER-positive and HER2-
negative on central review. Agreement between all three tests providing subtype assignment was 
obtained for 179 (59.3%) patients; 121 (40.1%) tumours classified as luminal A; 58 (19.2%) as all 
other subtypes. Discordant results across these tests were seen in 123 (40.7%) patients. Moderate 
agreement between tests was confirmed by Kappa statistics of 0·39 (95%CI 0·29-0·50) between 
BluePrint™ and MammaTyper™, 0·44 (95%CI 0·34-0·54) between Prosigna™ and 
MammaTyper™, and 0·55 (95%CI 0·45-0·64) between BluePrint™ and Prosigna™ subtype.  
 
Assessing relationship between the Prosigna™ subtyping and risk of recurrence score  
Prosigna™ is unique amongst the multi-parameter assays evaluated in providing both a 
subtype and a continuous risk of recurrence score (ROR) with pre-defined risk categories derived from 
an identical set of genes. All 178 tumours classified as luminal A had a ROR score below the 
predefined high risk cut-point and none of the 113 luminal B tumours were classified as low-risk 
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(Table 6). Eight tumours, all of which were centrally confirmed as ER-positive/HER2-negative 
were categorised into either the basal like (n=2) or HER2-like (n=6) subtypes and these were either 
intermediate or high risk by ROR score respectively. 
 
DISCUSSION 
The evaluation of candidate multi-parameter tests within OPTIMA prelim to determine the 
best assessment of risk stratification for the main OPTIMA study presented a clinically significant 
challenge given: 1) Evidence that these tests provide broadly similar prognostic information at the 
population level (26); 2) The use of markedly different gene panels to estimate the same endpoint; 
3) The use of different technologies including immunohistochemistry, PCR, quantitative and semi-
quantitative array based technologies.  
Previous in silico comparisons of multiple gene signatures have identified statistically 
significant discordance between different “diagnostic tests” (13;15-17). However, to date, this has 
been attributed to sub-optimal comparisons, since in the majority of studies genomic prediction 
scores have been estimated from published expression profiles. It has been argued that, in any 
direct comparison of validated diagnostic genomic assays, a high level of concordance could, and 
should be obtained (14). In the current study we performed such a direct comparison, each 
commercial assay was performed as prescribed by the relevant manufacturer (although the AQUA-
IHC4 assay used TMAs for convenience). What is striking is that, amongst five tests with robust 
independent technical and clinical validation as predictors of residual risk (MammaPrint™, 
Oncotype DX™, Prosigna™, IHC4 and IHC4-AQUA) and three that measure a recognised risk 
factor (molecular subtype) there is disagreement across all tests. Indeed for all tests the level of 
agreement was “moderate” as defined by Prat et al, reaching only level 3 reproducibility (қ0.40-
0.59) (14) This suggests that agreement for risk classification between different molecular tests 
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applied to the same patient sample is on the level of agreement for pathological assessment of 
tumour grade.  
The observed disagreement in risk categorisation for 60.6% of cases raises questions as to 
how patient management may be impacted by the choice of test used for risk stratification. 
Interestingly there does not seem to be better correlation between tests at the extremes of their 
ranges (the very low and high risk tumours in our cohort) than in the mid-range. It was less 
common, although not infrequent, for tumours placed into the lowest risk group by one test to be 
assigned into the highest risk group by another.  
Each test is independently validated and adopted for prediction of risk of recurrence, so 
what should we do when they disagree?  Paradoxically the result of this study can be viewed as 
either predictable or unexpected, depending on perspective. From a purely biological and technical 
perspective it is entirely predictable that tests which measure fundamentally different genes using 
different technologies give dissimilar results even when each individual assay remains technically 
valid. For example MammaPrint™ and Prosigna™, despite measuring the broadest range of genes 
(70 and 50 respectively) have only three genes in common and use different technical approaches 
(27;28). Even those tests measuring the same genes (IHC4, IHC4-AQUA and MammaTyper™) 
use different technologies (PCR versus IHC) or different antibodies, detection and quantification 
methods.  
From a clinical perspective the disagreement between multiple tests each assessing residual 
risk is highly perplexing. The disagreement extends to an inability to demonstrate strong 
agreement on molecular subtyping between tests which again seems counter-intuitive. However, 
it is less surprising that disagreement between molecular subtyping, in this context predominantly 
between luminal A and luminal B, should exist in the absence of any clinical or molecular 
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agreement as to the true boundary between a “luminal A” and “luminal B” cancer (16). Again, the 
Prosigna™ and BluePrint™ tests for subtyping have minimal gene overlap with only seven genes 
in common.  
What about risk prediction? The prediction of disease recurrence based on clinico-
pathological and molecular features of a cancer is notoriously challenging within populations and 
even more so at the individual patient level. Biologically and clinically aggressive cancers which, 
if left untreated, are destined to progress may be “cured” by surgery, radiotherapy, chemotherapy 
or endocrine therapy. Tests predicting risk, therefore face an important challenge in that they seek 
to measure both the risk of recurrence based on the biology of tumours and must function within 
a clinical setting where biology may reflect risk that is not realised due to medical intervention. 
What then can we learn from comparisons between validated assays that seek to stratify patients 
by risk of recurrence, if indeed we can learn anything? We argue that there is value in such 
comparisons, even in the absence of outcome data. Each test applied in this study is externally 
validated and adopted or available for adoption in multiple clinical jurisdictions (6;27-32). 
However none is, or claims to be, the ultimate discriminator of risk for patients. This study suggests 
there is more than one way of predicting residual risk.  
Our study is not without limitations. Whilst unable to determine subtle nuances in the 
performance of different tests within this population, we also recognise that existing data, both 
from the original studies validating individual tests and from comparisons, at a population level, 
of test performance in a single population (10-12) cannot provide a clear discrimination between 
them. No outcome data from OPTIMA prelim were available at the time of analysis. As the sample 
size is comparatively small it is highly unlikely that it will prove possible to compare the ability 
of the tests studied here to predict patient outcome. 
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In conclusion, in the widest and most comprehensive patient level direct diagnostic 
comparisons to date between multi-parametric tests of “residual risk” (after local treatment and 
endocrine therapy) we present further data that the proportions of patients identified as low, 
intermediate or high risk are broadly similar irrespective of which test is employed. However, both 
with respect to risk stratification and molecular sub-typing, marked differences were observed 
when categorisation of individual patients was considered. Such data, when considered with 
existing data on efficacy comparisons between different tests, support the conclusion that many 
current risk stratification tools are broadly equivalent and that further improvements in both 
prediction of relapse risk and therapeutic targeting would be of clinically significant value for 
patients at high risk of disease relapse (14). 
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Table 1: Characteristics of the 302 patients 
Characteristic 
Total 
n % 
Age years, Median(Range) 58 (40-78) 
Menopausal status of participant   
Pre/peri-menopausal 97 32.1 
Postmenopausal 205 67.9 
Number of involved nodes   
None 57 18.9 
1-3 192 63.6 
4-9 42 13.9 
+ve sentinel node biopsy without clearance 
surgery 
11 3.6 
Histological grade   
1 19 6.3 
2 201 66.6 
3 82 27.1 
Largest tumour size in mm, Median(Range) 28 (2-170) 
<=30mm 172 57.0 
>30mm 130 43.0 
Lymphovascular invasion reported   
No 169 56.0 
Yes 122 40.4 
Not Known 11 3.6 
Tumour type   
Ductal 214 70.9 
Lobular 65 21.5 
Tubular/Cribriform 2 0.7 
Mucinous 4 1.3 
Micropapillary 1 0.3 
Mixed 16 5.3 
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Table 2: Clinical risk of patients (n=302) 
Risk of Patient Median (range) 
Nottingham Prognostic Index 4·6 (2·8-8·2) 
≤3.4, No. (%) 12 (4.0%) 
>3.4 - ≤5.4, No. (%) 226 (74.8%) 
>5.4, No. (%) 64 (21.2%) 
PREDICT 10 year overall survival (%) 
Endocrine therapy only 77·0 (25·1-94·6) 
Chemotherapy and endocrine therapy 82·6 (39·8-95·9) 
Additional benefit of chemotherapy 5·5 (1·2-25·8) 
Adjuvant! 10 year risk overall survival (%) 
Endocrine therapy only 68·6 (25·4-90·4) 
Chemotherapy and endocrine therapy 76·4 (31·0-93·6) 
Additional benefit of chemotherapy 6·8 (1·2-25·8) 
Adjuvant! 10 year relapse free survival (%) 
Endocrine therapy only 60·5 (22·0-82·1) 
Chemotherapy and endocrine therapy 72·9 (29·1-89·4) 
Additional benefit of chemotherapy 10·5 (2·7-33·3) 
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Table 3: Risk categorisation by each test 
Risk group Oncotype DX* MammaPrint† Prosigna IHC4 
IHC4-
AQUA‡ 
No (%) 301 (99·7%) 298 (98.9%) 299 
(99.0%) 
257 
(85.1%) 
271 (89.7%) 
Low risk 163 (54.2%) 183 (61.4%) 108 
(36.1%) 
62 
(24.1%) 
87 (32.1%) 
Intermediate risk  84 (27.9%) -- 88 (29.4%) 123 
(47.9%) 
80 (29.5%) 
Mid risk -- -- -- -- 55 (20.3%) 
High risk 54 (17.9%) 115 (38.6%) 103 
(34.5%) 
72 
(28.0%) 
49 (18.1%) 
 
 
*Oncotype DX is divided into three risk groups with intermediate defined as Recurrence Score 
18-25 for the current analysis.  
†MammaPrint divides tumours into two risk groups only.  
‡IHC4-AQUA divides tumours into four risk groups: low, low-mid (here called intermediate), 
mid and high (combined as high risk). 
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 Table 4: Kappa statistics and 95% confidence interval (CI) for tests providing risk 
predictions* 
Test 
MammaPrint 
(Low), Kappa 
statistic 
(95%CI) 
Prosigna 
(Low/ 
Intermediate)
, Kappa 
statistic 
(95%CI) 
IHC4 
(Low/ 
Intermediate), 
Kappa 
statistic 
(95%CI) 
IHC4-AQUA† 
(Low/Low-Mid), 
Kappa statistic 
(95%CI) 
Oncotype DX (Recurrence 
Score ≤25) 
0·40  
(0·30-0·49) 
0·44 
(0·33-0·54) 
0·53  
(0·41-0·65) 
0·40 
(0·30-0·51) 
MammaPrint -- 0·53 
(0·43-0·63) 
0·33 
(0·21-0·44) 
0·42 
(0·30-0.53) 
Prosigna 
(Low/Intermediate) 
-- -- 0·39 
(0·27-0·50) 
0·43 
(0·31-0·54) 
IHC4 
(Low/Intermediate) 
-- -- -- 0·60 
(0·50-0·70) 
 
 
*Kappa statistics are for agreement between categorisation into combined low and intermediate 
risk versus high risk.  
†IHC4-AQUA mid risk and high risk are combined for this analysis. 
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Table 5: Number of tests agreeing with each test 
 
Number of other 
tests agreed with 
test 
Oncotype DX, 
No (%) 
Prosigna, 
No (%) 
MammaPrint, 
No (%) 
IHC4,  
No (%) 
IHC4-AQUA, 
No (%) 
4 119 (39.4%) 119 
(39.4%) 
119 (39.4%) 119 
(39.4%) 
119 (39.4%) 
3 84 (27.8%) 77 (25.5%) 73 (24.2%) 67 (22.2%) 75 (24.8%) 
2 54 (17.9%) 52 (17.2%) 47 (15.6%) 36 (11.9%) 33 (10.9%) 
1 31 (10.3%) 33 (10.9%) 34 (11.2%) 25 (8.3%) 27 (9.0%) 
0 13 (4.3%) 18 (6.0%) 25 (8.3%) 10 (3.3%) 17 (5.6%) 
Missing 1 (0.3%) 3 (1.0%) 4 (1.3%) 45 (14.9%) 31 (10.3%) 
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Table 6: Relationship between Prosigna subtyping and the continuous risk of recurrence (ROR) 
score  
Prosigna test result 
Subtype 
Luminal A 
No (%) 
Luminal B 
No (%) 
Basal like 
No (%) 
HER2 enriched  
No (%) 
No. of patients 178 (59.5%) 113 (37.8%) 2 (0.7%) 6 (2.0%) 
Median ROR (Inter-quartile range) 
 Range 
37 (28-44) 
5-59 
70 (63-78) 
43-96 
53 (47-58) 
47-58 
76 (72-78) 
64-84 
Risk Groups      
Low Risk  108 (60.7%) 0 0 0 
Intermediate Risk  70 (39.3%) 16 (14.2%) 2 (100%) 0 
High Risk  0 97 (85.8%) 0 6 (100%) 
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Figure Legend 
Figure 1: Agreement charts for two by two comparison of tests according to risk groups. A) 
Prosigna against Oncotype DX; B) IHC4 against Oncotype DX; C) IHC4-AQUA against 
Oncotype DX; D) IHC4 against Prosigna; E) IHC4-AQUA against Prosigna; F) IHC4 against 
IHC4-AQUA. Only tests that provide three risk categories are included in this analysis. The 
Oncotype DX intermediate risk group is defined as RS 18-25. The IHC4-AQUA mid risk group 
was combined with the high risk group. Rectangles are drawn for each level of the test outcomes, 
i.e. low, intermediate and high risk, based on the row and column cumulative totals. Thus for the 
low risk rectangle of the test 1 vs test 2 comparison, all tumours categorised as low risk by either 
test are included. The boundaries of the rectangles along both axes represent the number of 
tumours that were categorised as that outcome for each test. Black squares within the rectangles 
represent exact agreement between the levels of the two tests, e.g. both low scores, and are of 
size based on the cell frequencies and located according to the cumulative totals of the previous 
levels. Grey rectangles represent partial agreement, where the scores from one test are within one 
level of those from the other test, i.e. a low score on one test but intermediate on the other test. 
White areas within the rectangle reflect disagreement by more than level, i.e. low scores on one 
test and high scores on the other test. 
 
 
